Workflow
成都先导:上半年营收2.27亿元 同比增长16.58%

Core Insights - Chengdu Xian Dao reported a significant increase in revenue and profit for the first half of 2025, with total revenue reaching 227 million yuan, a year-on-year growth of 16.58%, and a net profit attributable to shareholders of 50.04 million yuan, up 390.72% [2][3] Financial Performance - The company achieved a net cash flow from operating activities of 111 million yuan, reflecting a year-on-year increase of 51.48% [2] - The overall gross margin for the main business was 53.82%, an increase of 7.23 percentage points compared to the previous year [2] Business Segments - The DEL segment, a cornerstone of Chengdu Xian Dao's business, generated revenue of 102 million yuan, marking a growth of 40.45% [3] - The UK subsidiary Vernalis confirmed milestone revenue, contributing to the steady development of the FBDD/SBDD platform [3] - The OBT segment expanded its traditional nucleoside monomer synthesis business while achieving commercial transformation of small nucleic acid one-stop projects [3] - The TPD segment actively explored new business models and initiated new project collaborations based on PROTAC technology [3] - The ChemSer segment saw a remarkable revenue increase of 94.17% due to the efficient operation of the automated high-throughput chemical synthesis platform [3] Market Strategy - The company is leveraging a global perspective to deepen collaborations and optimize international market strategies, enhancing operational efficiency and market positioning [3] - Chengdu Xian Dao is committed to advancing its technological platforms and research projects while exploring commercialization opportunities [3] Leadership Perspective - The CEO, Dr. Li Jin, emphasized the company's ongoing positive development and commitment to innovation-driven growth, aiming to create sustainable value for shareholders, clients, and society [4]